Orchestra Biomed Hldgs Inc (OBIO)

May 12, 2025, 4:28 PM EDT - 1 day ago

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

May 7, 2025, 8:30 AM EDT - 6 days ago

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

Apr 29, 2025, 9:00 AM EDT - 14 days ago

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Apr 28, 2025, 4:30 PM EDT - 15 days ago

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Apr 23, 2025, 9:00 AM EDT - 20 days ago

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

MDT

Apr 22, 2025, 7:00 AM EDT - 21 days ago

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Mar 31, 2025, 4:21 PM EDT - 6 weeks ago

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

Feb 20, 2025, 8:00 AM EST - 2 months ago

Orchestra BioMed to Present at Upcoming Investor Conferences

Feb 18, 2025, 8:00 AM EST - 3 months ago

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

Feb 12, 2025, 10:43 AM EST - 3 months ago

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Feb 5, 2025, 8:00 AM EST - 3 months ago

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Nov 26, 2024, 4:05 PM EST - 6 months ago

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 4:12 PM EST - 6 months ago

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Aug 12, 2024, 4:20 PM EDT - 9 months ago

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

May 22, 2024, 8:43 AM EDT - 1 year ago

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

May 13, 2024, 4:58 PM EDT - 1 year ago

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Mar 27, 2024, 4:17 PM EDT - 1 year ago

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

Mar 7, 2024, 8:00 AM EST - 1 year ago

Orchestra BioMed to Participate in Upcoming Investor Conferences

Mar 6, 2024, 8:37 AM EST - 1 year ago

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Jan 8, 2024, 7:30 AM EST - 1 year ago

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Nov 13, 2023, 4:21 PM EST - 1 year ago

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

Sep 19, 2023, 7:30 AM EDT - 1 year ago

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Aug 10, 2023, 4:34 PM EDT - 1 year ago

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 8, 2023, 8:30 AM EDT - 1 year ago

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

Jun 7, 2023, 8:30 AM EDT - 2 years ago

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

May 12, 2023, 9:15 AM EDT - 2 years ago

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

Feb 24, 2023, 8:00 AM EST - 2 years ago

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

Jan 27, 2023, 8:00 AM EST - 2 years ago

Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model

Jul 5, 2022, 8:00 AM EDT - 3 years ago

Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2